TuHURA Biosciences HURA
NASDAQ HURA
$2.00 -0.22 (-9.91%)
At close: Aug 21, 2026 · 4:00 PM EDT

TuHURA Biosciences (HURA) Convertible Debt (2023)

TuHURA Biosciences (HURA) posted quarterly Convertible Debt of $2.3 million for Q4 2023.

TuHURA Biosciences (HURA) Convertible Debt (2023) Analysis & Trends

TuHURA Biosciences' Convertible Debt history runs 1 years deep, the most recent figure standing at $2.3 million for Q4 2023.

  • In Q4 2023, Convertible Debt changed N/A year-over-year to $2.3 million; the TTM figure through Dec 2023 stood at $2.3 million (changed N/A YoY), while the FY2023 annual figure was $2.3 million, changed N/A from the prior year.
  • Convertible Debt for Q4 2023 stood at $2.3 million.
  • The five-year high for Convertible Debt was $2.3 million in Q4 2023, with the low at $2.3 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 TuHURA Biosciences 37.61 Mn 37.61 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 2.32 Mn